Verona Pharma plc
Verona Pharma plc is listed today as Verona Pharma plc: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2020 | $200 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jun 2016 | $45 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Verona Pharma plc chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2020
That is all the official record says: Verona Pharma plc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Verona Pharma plc are on record.
Investors#
No investor of Verona Pharma plc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Claire W. Poll | Executive officer | Jul 2020 |
| David Zaccardelli | Executive officer | Jul 2020 |
| Kathleen W. Rickard | Executive officer | Jul 2020 |
| Mark W. Hahn | Executive officer | Jul 2020 |
| Jan-Anders Karlsson | Executive officer | Jul 2016 |
| Kenneth Newman | Executive officer | Jul 2016 |
| Peter Spargo | Executive officer | Jul 2016 |
| Anders W. Ullman | Director | Jul 2020 |
| Andrew W. Sinclair | Director | Jul 2020 |
| David W. Ebsworth | Director | Jul 2020 |
| David Zaccardelli | Director | Jul 2020 |
| Ken W. Cunningham | Director | Jul 2020 |
| Mahendra W. Shah | Director | Jul 2020 |
| Martin W. Edwards | Director | Jul 2020 |
| Rishi W. Gupta | Director | Jul 2020 |
| Vikas W. Sinha | Director | Jul 2020 |
| Anders Ullman | Director | Jul 2016 |
| David Ebsworth | Director | Jul 2016 |
| Jan-Anders Karlsson | Director | Jul 2016 |
| Ken Cunningham | Director | Jul 2016 |
| Patrick Humphrey | Director | Jul 2016 |
About
Company in London, United Kingdom.
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.